Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE". In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2017, 2017, roč. 12, č. 6, s. 453.